Semaglutide

Semaglutide is a long-acting GLP-1 receptor agonist with one of the deepest clinical-trial datasets in metabolic medicine. It supports glucose-dependent…

A long-acting GLP-1 receptor agonist extensively studied for metabolic health.

Semaglutide is a long-acting GLP-1 receptor agonist with one of the deepest clinical-trial datasets in metabolic medicine. It supports glucose-dependent insulin secretion, slows gastric emptying, and acts on central appetite pathways.

Overview

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It is one of the most-studied incretin-class molecules and underpins several FDA-approved branded medications in clinical settings.

Mechanism of action

Semaglutide mimics endogenous GLP-1, stimulating glucose-dependent insulin secretion, slowing gastric emptying, and acting on central appetite-regulation pathways.

Researched applications

• Metabolic and weight-management research
• Glycemic regulation studies
• Appetite-pathway research

Quick facts

Property	Detail
Class	GLP-1 receptor agonist (incretin mimetic)
Half-life	~7 days
Dosing cadence	Once weekly (clinical)
Molecular weight	~4,114 Da
Storage	Lyophilized: freezer/refrigerator. Reconstituted: 2–8 °C, ≤28 days
Diluent	Bacteriostatic water

Half-life

Reported half-life: Approximately 7 days.

Commonly researched alongside

• B-12 / lipotropics in compounded formulations
• Tirzepatide considered as alternative, not stack

Other metabolic & weight peptides

Semaglutide sits in our metabolic & weight category. These are the other compounds in the same category, useful when you are deciding which reference page to read next.

• Tirzepatide — Dual GIP and GLP-1 receptor agonist studied for metabolic and weight outcomes.
• Retatrutide — Triple-receptor (GLP-1 / GIP / glucagon) agonist in late-stage clinical trials.

Semaglutide head-to-head

• Semaglutide vs Tirzepatide: Side-by-side comparison of the two leading incretin peptides: mechanism, half-life, head-to-head trial data, and how to think about them.
• Semaglutide vs Retatrutide: Single-receptor incretin vs the leading triple-receptor next-generation molecule. What the early phase-2 retatrutide data actually shows.
• Semaglutide vs Mazdutide: Single-receptor GLP-1 vs dual GLP-1/glucagon: how the established incretin compares to Innovent's Asia-first next-generation candidate.

Storage and shelf life

State	Conditions	Shelf life
Lyophilized (Powder)	Refrigerate 2–8°C (36–46°F) or freeze	12–24 months refrigerated; longer frozen
Reconstituted	Refrigerate 2–8°C only; no freezing	21–30 days typically
In Transit	Insulated packaging; ice packs	Minimize time; avoid heat exposure
MK-677 (Oral)	Room temp okay; cool/dry preferred	Per manufacturer; typically 12+ months

Sources

• Semaglutide — FDA prescribing information (Wegovy) — U.S. FDA (accessed 2026-06-13): https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf
• Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — NEJM / PubMed (accessed 2026-06-13): https://pubmed.ncbi.nlm.nih.gov/33567185/

Review status

This reference page was last reviewed on 2026-06-13 by the Clarity Wellness editorial team.

Important

All peptide products referenced are intended solely for research, investigational, or licensed professional use. They are not FDA-approved and are not intended to diagnose, treat, cure, or prevent any disease. Consult a licensed medical practitioner before any personal or clinical use.

Frequently asked questions

How is semaglutide different from tirzepatide?

Semaglutide targets the GLP-1 receptor alone. Tirzepatide is a dual GIP/GLP-1 receptor agonist, hitting two incretin pathways at once.

Do I need a prescription for clinical use?

Yes. Any clinical use must be directed by a licensed medical practitioner. Research-use product is supplied for investigational purposes only.

How long does semaglutide stay active?

Semaglutide has a half-life around 7 days, which supports once-weekly dosing in clinical protocols.